Royal Bank Of Canada Precision Biosciences Inc Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.29 - $0.45 $57 - $88	-197 Reduced 57.77%	144 $0
Q3 2023 Nov 14, 2023	SELL	$0.34 - $0.69 $852 - $1,729	-2,507 Reduced 88.03%	341 $0
Q2 2023 Aug 14, 2023	BUY	$0.52 - $0.91 $568 - $994	1,093 Added 62.28%	2,848 $1,000
Q1 2023 May 15, 2023	BUY	$0.7 - $1.41 $1,073 - $2,162	1,534 Added 694.12%	1,755 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.97 - $45.0 $1,167 - $54,180	-1,204 Reduced 84.49%	221 $0
Q3 2022 Nov 14, 2022	BUY	$1.22 - $40.8 $1,562 - $52,264	1,281 Added 889.58%	1,425 $2,000
Q2 2022 Aug 15, 2022	SELL	$1.15 - $3.34 $57,786 - $167,831	-50,249 Reduced 99.71%	144 $0
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $73,461 - $192,587	-24,818 Reduced 33.0%	50,393 $155,000
Q4 2021 Feb 14, 2022	BUY	$7.4 - $11.66 $85,211 - $134,264	11,515 Added 18.08%	75,211 $557,000
Q3 2021 Nov 15, 2021	SELL	$9.18 - $14.15 $56,043 - $86,385	-6,105 Reduced 8.75%	63,696 $735,000
Q2 2021 Aug 16, 2021	BUY	$8.07 - $12.52 $563,294 - $873,908	69,801 New	69,801 $874,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.